Status:
COMPLETED
VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers
Lead Sponsor:
Venatorx Pharmaceuticals, Inc.
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Bacterial Infections
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is a 2-part, drug-drug interaction study to evaluate potential PK interactions after single doses in Part 1 and multiple doses in Part 2. In Part 1, subjects will receive single dose of 5 treatme...
Eligibility Criteria
Inclusion
- Healthy adults
- Males or non-pregnant, non-lactating females
- Body Mass Index (BMI) between 18.5 - 32.0, inclusive
- Weight greater than or equal to 50 kg
- Suitable veins for cannulation
Exclusion
- Employee of site or the sponsor
- Any disease that poses an unacceptable risk to participants
- Abnormal ECG
- Abnormal labs
- Abnormal vital signs
- Current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, autoimmune, hematologic, neoplastic, or neurological disorder
- Positive serology for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) type 1
Key Trial Info
Start Date :
October 24 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2017
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT03332732
Start Date
October 24 2017
End Date
December 20 2017
Last Update
October 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PRAHS
Lenexa, Kansas, United States, 66219